Alkermes Pharma Ireland Limited

David Manser

Kristopher Perkin

Tarek A Zeidan

Magali B Hickey

Brian Steinberg

Philip Cresswell

Elaine Liversidge

Greg Smith

Paul Hurley

Renato A Chiarella

Hector Guzman

Stephen B Ruddy

Gary G Liversidge

Scott Jenkins

Gurvinder Singh Rekhi

Michael J Palmieri, Jr

Marjie L Hard

Deborah Neville

Ethan P Cash

Ryan Turncliff

Sara Montminy Paquette

Magali Hickey

Tarek Zeidan

Jr Palmieri Michael

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

Immediate release multilayer tablet

Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.

Aripiprazole prodrug composition

Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.

Compositions of multiple aripiprazole prodrugs

Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilization of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.

Aripiprazole prodrug compositions

Described are compositions of stable nanoparticulate cinacalcet or a salt thereof, and methods of making and using them. The compositions exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions.

Nanoparticulate cinacalcet compositions

Growing community of inventors

Keenagh, Ireland

David Manser